Seqens Seqens

X
[{"orgOrder":0,"company":"InGeneron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Finds InGeneron's Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder Function","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed"},{"orgOrder":0,"company":"InGeneron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InGeneron Reports Positive Long-Term Results for its Cell Therapy in Partial-Thickness Rotator Cuff Tears","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by InGeneron

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Transpose RT cell therapy platform consists of a processing unit, a set of disposables, and Matrase™, a proprietary enzyme mixture, which is investigated for treatment of Partial-Thickness Rotator Cuff Tears.

            Lead Product(s): Transpose RT Cell Therapy

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Study reveals favorable results using regenerative cells isolated from patients’ own body fat prepared with the Transpose® RT System in the Journal of Orthopaedic Surgery and Research.

            Lead Product(s): Autologous adipose-derived regenerative cells

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 07, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY